Which companies overlap with Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina's portfolio?

Top competitors by shared drug class: Baxter Healthcare Corporation, Brigham and Women's Hospital, Hellenic Society of Hematology, John van den Anker, Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fundacio-d-investigacio-en-atencio-primaria-jordi-gol-i-gurina.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina pipeline: 7 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

7 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Fosfomycin Trometamol Salt	Fosfomycin Trometamol Salt	marketed
Hydroxide Potassium	Hydroxide Potassium	marketed
Ipratropium Bromide 20Micrograms Inhaler	Ipratropium Bromide 20Micrograms Inhaler	marketed
Complete a 7-day course	Complete a 7-day course	marketed
Dextromethorphan 15 milligrams	Dextromethorphan 15 milligrams	marketed
Non- effervescent Paracetamol kern	Non- effervescent Paracetamol kern	marketed	Analgesic and antipyretic	Cyclooxygenase (COX-1, COX-2)	Pain Management
Effervescent paracetamol termalgin	Effervescent paracetamol termalgin	marketed	Analgesic and antipyretic	Cyclooxygenase (COX)	Pain management

Therapeutic area mix

Pain Management · 1
Pain management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Baxter Healthcare Corporation · 1 shared drug class
Brigham and Women's Hospital · 1 shared drug class
Hellenic Society of Hematology · 1 shared drug class
John van den Anker · 1 shared drug class
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 1 shared drug class
Mallinckrodt · 1 shared drug class
Maoxiang Group Jilin Pharmaceutical Co., Ltd. · 1 shared drug class
Ain Shams University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina:

Cite this brief

Drug Landscape (2026). Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fundacio-d-investigacio-en-atencio-primaria-jordi-gol-i-gurina. Accessed 2026-05-16.